| imfinzi durvalumab biggest competitor in cost | 1.66 | 0.7 | 3463 | 45 | 12 |
| imfinzi durvalumab biggest cost | 1.51 | 0.8 | 231 | 31 | 74 |
| imfinzi durvalumab biggest comparison | 0.01 | 0.1 | 4368 | 37 | 7 |
| imfinzi durvalumab biggest company | 1.92 | 0.1 | 5022 | 34 | 8 |
| imfinzi durvalumab biggest collaboration | 0.31 | 0.9 | 9367 | 40 | 46 |
| imfinzi durvalumab biggest controversy | 1.59 | 0.2 | 6366 | 38 | 60 |
| imfinzi durvalumab biggest customer | 1.85 | 1 | 7835 | 35 | 74 |
| imfinzi durvalumab biggest clinical trial | 1.31 | 0.7 | 4357 | 41 | 25 |
| imfinzi durvalumab biggest challenge | 0.68 | 0.1 | 5825 | 36 | 30 |
| imfinzi durvalumab biggest commercial | 0.1 | 0.4 | 3689 | 37 | 53 |
| imfinzi biggest competitor in cost | 0.8 | 0.7 | 2196 | 34 | 73 |
| imfinzi biggest competitor in clinical trials | 1.33 | 0.2 | 3338 | 45 | 50 |
| imfinzi biggest competitor in market share | 1.16 | 0.1 | 9977 | 42 | 40 |
| durvalumab imfinzi package insert | 2 | 0.4 | 5180 | 33 | 31 |
| imfinzi biggest competitor in survival rates | 0.9 | 1 | 3246 | 44 | 18 |
| imfinzi biggest competitor in oncology | 0.57 | 0.9 | 3665 | 38 | 100 |
| imfinzi biggest competitor in immunotherapy | 1.51 | 0.2 | 8305 | 43 | 61 |
| imfinzi durvalumab side effects | 1.44 | 0.7 | 3915 | 31 | 77 |
| j code for imfinzi durvalumab | 0.67 | 0.4 | 7264 | 29 | 18 |
| imfinzi biggest competitor in lung cancer | 0.14 | 0.6 | 2697 | 41 | 95 |
| cpt code for durvalumab imfinzi | 0.49 | 0.8 | 2451 | 31 | 42 |
| how much does durvalumab cost | 1.89 | 0.3 | 9052 | 29 | 46 |
